EMERALD study schedule of events
| Baseline | 2 months postdischarge | 3–9 months postdischarge | 12 months postdischarge | |
| Informed consent | X Part A | X* Part B | ||
| Demographics | X | |||
| IES-R | X | X | X | |
| CAPS-5, CGI-S* | X* | X* | ||
| PHQ-9 | X | X | X | |
| GAD-7 | X | X | X | |
| EQ-5D-5L | X | X | X | |
| EMDR intervention | X* | |||
| IES-R, PHQ-9, GAD-7 (EMDR group only) | ||||
| Randomisation preference* | X* | |||
| Process evaluation | X | X |
X* for participants consenting to part B of the study only.
CAPS-5, Clinician Administered PTSD Scale for DSM-5; CGI-S, Clinical Global Impression of Illness Severity; EMDR, eye-movement desensitisation and reprocessing; EQ-5D-5L, EuroQol-5 Dimensions-5 Levels; GAD-7, Generalised Anxiety Disorder 7; IES-R, Impact of Events Scale-Revised; PHQ-9, Patient Health Questionnaire-9; PTSD, post-traumatic stress disorder; QoL, quality of life; RCT, randomised controlled trial.